generation of superoxide radicals).' Chemotactic defects frequently result in cutaneous infections.4 During MTX therapy no significant changes in circulating T-cell population and T-cell activity are found. On the basis of these findings an increase in both cutaneous infections and prolonged and recurrent infections with staphylococcus, gram-negative organisms and fungi is to be expected during MTX treatment. In a few cases opportunistic infections have been reported in patients on MTX, sometimes in combination with corticosteroids.5-l0 To our knowledge no prospective studies have been performed to estimate the frequency of infection in either RA patients or MTX-treated patients with RA.
In this prospective study the occurrence of infections, especially infections of the respiratory and urinary tracts and the skin, was investigated in a group of patients with RA on MTX therapy and a group of control patients with RA on other antirheumatic drugs. At the start of the study, data on infections in the preceding year were collected; retrospective and prospective data were compared. (table 1) . 17
No differences in other disease characteristics 12 (rheumatoid factor positivity, disease duration) 3 were found.
*Significantly different between groups, p < 0-01 (Chi square). Table 3 shows reported infections and reported use of antibiotics for both groups. In In the MTX group more sinusitis and miscellaneous infections were reported whereas influenza and colds were common in the control group, but these differences did not reach statistical significance. The category of miscellaneous infections consisted of herpes zoster (n = 4), herpes simplex (n = 5), varicella (n = 1), erysipelas (n = 3), infected joint prostheses (n = 3), vaginal infections (n = 2), prostatitis (n = 2), viral pericarditis (n = 1) and Candida stomatitis (n = 2). Three Comparison with the prospective data revealed that a significanly lower percentage of the patients reported infections retrospectively, in the MTX group as well as the control group. In the control group significantly fewer respiratory tract infections were reported retrospectively.
Discussion
The aim of this study was to determine whether the administration of low-dose MTX to patients with RA is associated with an increased risk of infection. Prospective selfreported patient information indicated that a significantly higher percentage of patients had had infections and used antibiotics in the MTX group than in a control group of patients with RA not on MTX therapy. The difference in overall infections was due mainly to an increased rate of skin infections and respiratory tract infections. Stratification for disease severity (functional class) only slightly reduced the relative risk for infections and use of antibiotics. Use of prednisone and duration of MTX therapy did not influence the occurrence of infections or the use of antibiotics. In this study draining ulcers surrounded by an indurated zone were regarded as skin infections. It is not always easy to determine clinically whether skin ulcers on fingers or toes are based on infection or on vasculitis; clear vasculitis, however, was not considered as an infection in this study.
Respiratory tract infections did not lead to discontinuation of MTX therapy. In two cases MTX was stopped because of fever and pulmonary infiltrates. Pathogenic microorganisms could not be isolated and since methotrexate pneumonitis could not be ruled out, MTX was stopped. In our clinic, all patients who start MTX therapy are asked routinely about pulmonary complaints and dyspnoea; medical examination, x rays and, if possible, lung function tests are performed. When one of the results is not satisfactory, MTX is not given. By excluding patients with pulmonary problems from treatment with MTX, we made a selection concerning respiratory problems which favoured the MTX group. The higher incidence of respiratory tract infections found for the MTX group cannot therefore be explained by baseline differences in pulmonary status.
In previous reports opportunistic infections have been reported in patients using MTX. In our clinic we have seen one Nocardia infection and one very serious multidermatome herpes zoster infection in RA patients on MTX. [5] [6] [7] [8] [9] [10] During this study three patients (4%) of the MTX group experienced a mild herpes zoster infection, which did not necessitate withdrawal of MTX, versus one patient (0-6%) of the control group. Although our numbers on this specific infection are too small to draw conclusions, this finding seems to agree with those reported by Antonelli: herpes zoster may occur more frequently in patients with RA on MTX therapy although it appears to be selflimiting and benign. 14 In the MTX group significantly more patients reported the use of antibiotics. This may be (partly) due to a 'doctor's bias'. Doctors may be more prone to prescribe antibiotics for a patient on MTX therapy than a patient who does not take such medication. The same could apply for patients with joint prostheses, although no increase in the number of infections or use of antibiotics was found for this subgroup compared with patients without joint prostheses.
Retrospective data on our group of patients were collected for comparison with findings in previous reports. The retrospectively reported overall frequency of infections did not differ significantly between the MTX group and the control group and was comparable with findings in other retrospective studies.' For both groups the percentage patients who reported infections was significantly higher during the prospective study than during the retrospective study, while the prospectively reported use of antibiotics did not differ significantly from the retrospective data (table 5) . These findings suggest that the use of antibiotics is probably remembered more easily than the occurrence of infections. In the control group the percentage of respiratory tract infections reported during the prospective study was significantly higher than the percentage found in the retrospective data. In the MTX group this difference was not statistically significant. This may be explained by the fact that the symptoms of respiratory tract disease received more emphasis (and therefore perhaps were recalled more easily) in the MTh group because of the detailed instructions usually given to both the patients and their general practitioners at the start of MTX treatment. These results underline an important disadvantage of retrospecive studies, that is, that some data are remembered more easily than other data and that it is not advisable to rely on peoples' memory if information is to be collected adequately.
In conclusion, in our study a significantly higher overall percentage of infections was found in the MTX group, mainly due to an increased occurrence of skin infections and respiratory tract infections. Antibiotics were used more frequently in the MTX group than in the control group. These differences were only partly explained by differences in disease severity (functional class) and were not related to duration of MTX therapy or use of prednisone. The increase of infections did not lead to serious illness or to severe complications necessitating withdrawal of the medication. 
